Table 1.

Effect of oral administration of 300 mg/kg genistein or DMSO on clinical signs of experimental autoimmune encephalomyelitis

		Incidence†	Onset (day)‡	Maximum clinical score‡
Treatment began at the onset of disease	DMSO	6/6	14.5±0.56	2.8±0.21
	Genistein	5/6	14.8±0.37	1.6±0.25 **
Treatment began after 30 days p.i.	DMSO	6/6	14.7±0.52	2.7±0.17
	Genistein	6/6	12.8±0.57	2.8±0.26

Gavaging with genistein (300 mg/kg) at the onset of clinical signs significantly reduced maximum disease score.

^† Ratio,

^‡mean± SEM,

^*P< 0.05,

^**P< 0.005 compared to DMSO-gavaged group post induction